Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease

- First report of metabolic differences COPD vs. different stages of lung cancer (LC).
- Human serum NMR analysis.
- NMR metabolic fingerprints were modelled using OPLS-DA.
- Discriminant models allow to distinguish COPD vs. early and advanced LC patients.
- Metabolite biomarkers may prove to be useful in distinguishing lung cancer states.